Valneva (NASDAQ:VALN) Shares Gap Down – What’s Next?

Valneva SE (NASDAQ:VALN) shares gapped down prior to trading on Monday . The stock had previously closed at $7.03, but opened at $6.61. Valneva shares last traded at $6.40, with a volume of 9,012 shares traded.

Wall Street Analyst Weigh In

Several brokerages recently commented on VALN. Guggenheim cut their price objective on shares of Valneva from $17.00 to $15.00 and set a “buy” rating on the stock in a research report on Monday, March 24th. HC Wainwright restated a “buy” rating and issued a $17.00 price target on shares of Valneva in a research note on Tuesday, April 15th.

Valneva Stock Performance

The business’s 50-day simple moving average is $6.92 and its 200 day simple moving average is $5.69. The firm has a market cap of $547.82 million, a P/E ratio of -50.38 and a beta of 1.85. The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.25 and a current ratio of 2.78.

Valneva (NASDAQ:VALN) last posted its earnings results on Thursday, March 20th. The company reported ($0.54) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.32). The firm had revenue of $56.48 million during the quarter, compared to the consensus estimate of $55.64 million. Valneva had a negative net margin of 4.35% and a negative return on equity of 3.93%. As a group, equities analysts predict that Valneva SE will post 0.13 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. Wells Fargo & Company MN raised its holdings in Valneva by 14.3% in the 4th quarter. Wells Fargo & Company MN now owns 246,766 shares of the company’s stock worth $1,079,000 after purchasing an additional 30,859 shares during the period. ABC Arbitrage SA purchased a new position in shares of Valneva during the 4th quarter valued at about $84,000. Finally, GAMMA Investing LLC purchased a new stake in Valneva in the 1st quarter worth approximately $94,000. 11.39% of the stock is currently owned by institutional investors.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.